Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.86
RTRX's Cash to Debt is ranked lower than
66% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. RTRX: 0.86 )
Ranked among companies with meaningful Cash to Debt only.
RTRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 10000.00 Max: No Debt
Current: 0.86
Equity to Asset 0.59
RTRX's Equity to Asset is ranked lower than
56% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. RTRX: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
RTRX' s Equity to Asset Range Over the Past 10 Years
Min: -0.96  Med: -0.28 Max: 0.59
Current: 0.59
-0.96
0.59
Interest Coverage 175.78
RTRX's Interest Coverage is ranked higher than
70% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.94 vs. RTRX: 175.78 )
Ranked among companies with meaningful Interest Coverage only.
RTRX' s Interest Coverage Range Over the Past 10 Years
Min: 175.78  Med: 10000.00 Max: 9999.99
Current: 175.78
175.78
9999.99
F-Score: 4
WACC vs ROIC
11.79%
76.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 41.20
RTRX's Operating margin (%) is ranked higher than
96% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. RTRX: 41.20 )
Ranked among companies with meaningful Operating margin (%) only.
RTRX' s Operating margin (%) Range Over the Past 10 Years
Min: 41.18  Med: 353.41 Max: 2105.03
Current: 41.2
41.18
2105.03
Net-margin (%) 45.80
RTRX's Net-margin (%) is ranked higher than
97% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. RTRX: 45.80 )
Ranked among companies with meaningful Net-margin (%) only.
RTRX' s Net-margin (%) Range Over the Past 10 Years
Min: 45.78  Med: 354.18 Max: 2059.37
Current: 45.8
45.78
2059.37
ROE (%) 67.14
RTRX's ROE (%) is ranked higher than
98% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. RTRX: 67.14 )
Ranked among companies with meaningful ROE (%) only.
RTRX' s ROE (%) Range Over the Past 10 Years
Min: 89.25  Med: 89.25 Max: 89.25
Current: 67.14
ROA (%) 29.30
RTRX's ROA (%) is ranked higher than
97% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. RTRX: 29.30 )
Ranked among companies with meaningful ROA (%) only.
RTRX' s ROA (%) Range Over the Past 10 Years
Min: -375  Med: -240.01 Max: 36.19
Current: 29.3
-375
36.19
» RTRX's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RTRX Guru Trades in

Q2 2015

RTRX Guru Trades in Q2 2015

Steven Cohen 243,300 sh (New)
Joel Greenblatt 16,982 sh (New)
Louis Moore Bacon 85,000 sh (New)
Paul Tudor Jones 26,905 sh (New)
Jim Simons 80,500 sh (New)
» More
Q3 2015

RTRX Guru Trades in Q3 2015

Paul Tudor Jones 40,808 sh (+51.67%)
Joel Greenblatt 25,289 sh (+48.92%)
Jim Simons 100,913 sh (+25.36%)
Louis Moore Bacon Sold Out
Steven Cohen 194,000 sh (-20.26%)
» More
Q4 2015

RTRX Guru Trades in Q4 2015

Joel Greenblatt Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 26,665 sh (-34.66%)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 6.54
RTRX's P/E(ttm) is ranked higher than
95% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. RTRX: 6.54 )
Ranked among companies with meaningful P/E(ttm) only.
RTRX' s P/E(ttm) Range Over the Past 10 Years
Min: 5.44  Med: 8.38 Max: 24.07
Current: 6.54
5.44
24.07
PE(NRI) 5.01
RTRX's PE(NRI) is ranked higher than
96% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. RTRX: 5.01 )
Ranked among companies with meaningful PE(NRI) only.
RTRX' s PE(NRI) Range Over the Past 10 Years
Min: 4.2  Med: 6.47 Max: 15.28
Current: 5.01
4.2
15.28
Price/Owner Earnings (ttm) 4.05
RTRX's Price/Owner Earnings (ttm) is ranked higher than
95% of the 259 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.02 vs. RTRX: 4.05 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RTRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.38  Med: 6.36 Max: 30.45
Current: 4.05
3.38
30.45
P/B 1.83
RTRX's P/B is ranked higher than
72% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. RTRX: 1.83 )
Ranked among companies with meaningful P/B only.
RTRX' s P/B Range Over the Past 10 Years
Min: 1.52  Med: 2.66 Max: 8.33
Current: 1.83
1.52
8.33
P/S 2.39
RTRX's P/S is ranked higher than
58% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. RTRX: 2.39 )
Ranked among companies with meaningful P/S only.
RTRX' s P/S Range Over the Past 10 Years
Min: 1.97  Med: 24.54 Max: 76.25
Current: 2.39
1.97
76.25
EV-to-EBIT 5.26
RTRX's EV-to-EBIT is ranked higher than
96% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.51 vs. RTRX: 5.26 )
Ranked among companies with meaningful EV-to-EBIT only.
RTRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.1  Med: -18.65 Max: 83.1
Current: 5.26
-61.1
83.1
EV-to-EBITDA 4.67
RTRX's EV-to-EBITDA is ranked higher than
96% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.66 vs. RTRX: 4.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
RTRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -62.8  Med: -20.80 Max: 79.3
Current: 4.67
-62.8
79.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.64
RTRX's Price/Tangible Book is ranked lower than
53% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. RTRX: 3.64 )
Ranked among companies with meaningful Price/Tangible Book only.
RTRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.12  Med: 5.12 Max: 5.12
Current: 3.64
Price/Median PS Value 0.09
RTRX's Price/Median PS Value is ranked higher than
99% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. RTRX: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
RTRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.12 Max: 0.12
Current: 0.09
Price/Graham Number 0.86
RTRX's Price/Graham Number is ranked higher than
83% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. RTRX: 0.86 )
Ranked among companies with meaningful Price/Graham Number only.
RTRX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.54  Med: 0.67 Max: 1.19
Current: 0.86
0.54
1.19
Earnings Yield (Greenblatt) (%) 19.01
RTRX's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. RTRX: 19.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RTRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 12.50 Max: 22.1
Current: 19.01
1.2
22.1

More Statistics

Revenue(Mil) $256
EPS $ 2.30
Beta1.51
Short Percentage of Float15.27%
52-Week Range $11.60 - 37.04
Shares Outstanding(Mil)36.51

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 119 160 207
EPS($) 0.59 1.08 0.57
EPS without NRI($) 0.59 1.08 0.57

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:XKRX:000230, SZSE:000605, SZSE:300239, XKRX:067080, SHSE:600080, SHSE:600385 » details
Traded in other countries:17R.Germany,
Retrophin Inc was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for RTRX

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Largest Insider Buys of the Week Apr 07 2014 
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP Apr 07 2014 
Three CEOs Reporting Large Insider Buys Apr 04 2014 
Steven Cohen Tops GuruFocus' Real Time Picks of the Week Apr 04 2014 
Morning Coffee: See Which Insiders are Buying Apr 04 2014 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 
Weekly CEO Buys Highlight: KMI, CLMS, RTRX, OPK, KO Mar 03 2014 
Weekly CEO Buys Highlight: RSE, RHP, RTRX, CLMS Jan 21 2014 

More From Other Websites
Edited Transcript of RTRX earnings conference call or presentation 3-May-16 8:30pm GMT May 03 2016
RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 03 2016
Retrophin Reports First Quarter 2016 Financial Results May 03 2016
Retrophin Reports First Quarter 2016 Financial Results May 03 2016
Even more charges are probably coming Martin Shkreli’s way May 03 2016
U.S. prosecutors consider more charges against ex-CEO Shkreli May 03 2016
Q1 2016 Retrophin Inc Earnings Release - After Market Close May 03 2016
ETF’s with exposure to Retrophin, Inc. : April 29, 2016 Apr 29 2016
Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : April 28, 2016 Apr 28 2016
Retrophin to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 21 2016
Retrophin to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 21 2016
Retrophin to Report First Quarter 2016 Financial Results Apr 19 2016
Retrophin to Report First Quarter 2016 Financial Results Apr 19 2016
The Grave Dangers Of Concentration Apr 12 2016
RETROPHIN, INC. Files SEC form 8-K, Other Events Apr 11 2016
Retrophin, Inc. – Value Analysis (NASDAQ:RTRX) : April 8, 2016 Apr 08 2016
Retrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : April 7, 2016 Apr 07 2016
Kevin Kotler’s Healthcare Fund Broadfin Capital Just Had A Disastrous Q1 Apr 06 2016
Retrophin Names Gary A. Lyons Chairman of the Board of Directors Apr 04 2016
Retrophin Names Gary A. Lyons Chairman of the Board of Directors Apr 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK